PE20141004A1 - 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 - Google Patents
1,3-oxazinas como inhibidores de la bace1 y/o de la bace2Info
- Publication number
- PE20141004A1 PE20141004A1 PE2013002203A PE2013002203A PE20141004A1 PE 20141004 A1 PE20141004 A1 PE 20141004A1 PE 2013002203 A PE2013002203 A PE 2013002203A PE 2013002203 A PE2013002203 A PE 2013002203A PE 20141004 A1 PE20141004 A1 PE 20141004A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halogen
- oxazin
- fluor
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/28—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 4-(3-AMINO-FENIL)-5,6-DIHIDRO-4H-[1,3]OXAZIN-2-ILAMINAS DE FORMULA (I) DONDE R1 ES H, HALOGENO O ALQUILO(C1-C6); R2 ES H, ALQUILO(C1-C6) O HALOGENO-ALQUILO(C1-C3); R3 ES H O ALQUILO(C1-C6); R4 ES HALOGENO, ALQUILO(C1-C6) O HALOGENO-ALCOXI(C1-C6); R5 ES -C(=O)-R6, EN DONDE R6 ES HETEROARILO, CICLOALQUILO(C3-C6) O HETEROCICLILO OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: [3-((4R,5R)-2-AMINO-5-FLUOR-4-METIL-5,6-DIHIDRO-4H-[1,3]-OXAZIN-4-IL)-4-FLUOR-FENIL]-AMIDA DEL ACIDO 5-CLORO-PIRIDINA-2-CARBOXILICO; [3-((4R,5R)-2-AMINO-5-FLUOR-4-METIL-5,6-DIHIDRO-4H-[1,3]-OXAZIN-4-IL)-4-FLUOR-FENIL]-AMIDA DEL ACIDO 5-CIANO-PIRIDINA-2-CARBOXILICO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE OBTENCION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE BACE1 Y BACE2 SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, DIABETES TIPO 2
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11161803 | 2011-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141004A1 true PE20141004A1 (es) | 2014-08-27 |
Family
ID=45932341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013002203A PE20141004A1 (es) | 2011-04-11 | 2012-04-10 | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 |
Country Status (19)
Country | Link |
---|---|
US (3) | US8754075B2 (es) |
EP (1) | EP2697208A1 (es) |
JP (1) | JP5721157B2 (es) |
KR (1) | KR20140002039A (es) |
CN (1) | CN103502227A (es) |
AR (1) | AR085960A1 (es) |
AU (1) | AU2012241955A1 (es) |
CA (1) | CA2832467A1 (es) |
CL (1) | CL2013002871A1 (es) |
CO (1) | CO7071122A2 (es) |
CR (1) | CR20130432A (es) |
EA (1) | EA201391468A1 (es) |
EC (1) | ECSP13012967A (es) |
IL (1) | IL228104A0 (es) |
MA (1) | MA35114B1 (es) |
MX (1) | MX2013010795A (es) |
PE (1) | PE20141004A1 (es) |
SG (1) | SG193929A1 (es) |
WO (1) | WO2012139993A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101052122B1 (ko) | 2005-10-25 | 2011-07-26 | 시오노기세야쿠 가부시키가이샤 | 아미노디히드로티아진 유도체 |
AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
JP5383483B2 (ja) * | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
US8637504B2 (en) * | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
WO2010047372A1 (ja) * | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Bace1阻害活性を有する2-アミノピリミジン-4-オンおよび2-アミノピリジン誘導体 |
WO2011044184A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
EP2511268B2 (en) | 2009-12-11 | 2021-02-17 | Shionogi & Co., Ltd. | Oxazine derivative |
JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
CN103261199A (zh) | 2010-10-29 | 2013-08-21 | 盐野义制药株式会社 | 萘啶衍生物 |
WO2012138590A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US8754075B2 (en) * | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するbace1阻害剤 |
US8785436B2 (en) * | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
MX2013014007A (es) * | 2011-06-07 | 2014-03-12 | Hoffmann La Roche | [1,3] oxazinas. |
AU2012298983A1 (en) | 2011-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions and their use |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
AR089781A1 (es) * | 2012-01-26 | 2014-09-17 | Hoffmann La Roche | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas |
US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
JP6389830B2 (ja) * | 2013-03-01 | 2018-09-12 | アムジエン・インコーポレーテツド | ベータ−セクレターゼ阻害剤としてのパーフルオロ化5,6−ジヒドロ−4h−1,3−オキサジン−2−アミン化合物および使用方法 |
US9085576B2 (en) | 2013-03-08 | 2015-07-21 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
MY174747A (en) | 2013-04-11 | 2020-05-13 | Hoffmann La Roche | Bace1 inhibitors |
JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
CN106029639B (zh) | 2014-02-19 | 2019-01-08 | H.隆德贝克有限公司 | 治疗阿尔茨海默病的bace1抑制剂的2-氨基-3,5,5-三氟-3,4,5,6-四氢吡啶 |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
WO2016022724A1 (en) | 2014-08-08 | 2016-02-11 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
CN105566179B (zh) * | 2014-10-14 | 2017-09-05 | 上海工程技术大学 | 一种制备手性α‑氟‑β‑氨基酸衍生物的方法 |
CR20170187A (es) * | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
PE20171349A1 (es) | 2015-03-20 | 2017-09-13 | Hoffmann La Roche | Inhibidores de bace1 |
TW201717948A (zh) | 2015-08-10 | 2017-06-01 | H 朗德貝克公司 | 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療 |
US20180244645A1 (en) | 2015-08-12 | 2018-08-30 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors |
CN107304176A (zh) * | 2016-04-21 | 2017-10-31 | 上海工程技术大学 | α-芳基取代的α-氟代β-氨基酸类化合物及其制备方法 |
JP7353708B2 (ja) | 2018-04-27 | 2023-10-02 | 塩野義製薬株式会社 | 選択的bace1阻害活性を有するテトラヒドロピラノオキサジン誘導体 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9216298D0 (en) | 1991-08-15 | 1992-09-16 | Ici Plc | Piperidine derivatives |
WO1998057925A1 (en) | 1997-06-16 | 1998-12-23 | American Home Products Corporation | Elevation of hdl cholesterol by 2-[(aminothioxomethyl)-hydrazono]-2-arylethyl carbamates |
KR101052122B1 (ko) * | 2005-10-25 | 2011-07-26 | 시오노기세야쿠 가부시키가이샤 | 아미노디히드로티아진 유도체 |
AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
US20090209757A1 (en) | 2008-01-10 | 2009-08-20 | Santiago Ini | Processes for the preparation and purification of paliperidone palmitate |
CN101910143B (zh) | 2008-01-18 | 2013-08-21 | 卫材R&D管理有限公司 | 稠合的氨基二氢噻嗪衍生物 |
WO2010113848A1 (ja) | 2009-03-31 | 2010-10-07 | 塩野義製薬株式会社 | Bace1阻害作用を有するイソチオウレア誘導体またはイソウレア誘導体 |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
AR077328A1 (es) | 2009-07-24 | 2011-08-17 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos |
US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
US7964594B1 (en) * | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
EP2511268B2 (en) * | 2009-12-11 | 2021-02-17 | Shionogi & Co., Ltd. | Oxazine derivative |
US8754075B2 (en) * | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
-
2012
- 2012-04-05 US US13/439,893 patent/US8754075B2/en not_active Expired - Fee Related
- 2012-04-10 CA CA2832467A patent/CA2832467A1/en not_active Abandoned
- 2012-04-10 JP JP2014504274A patent/JP5721157B2/ja not_active Expired - Fee Related
- 2012-04-10 AU AU2012241955A patent/AU2012241955A1/en not_active Abandoned
- 2012-04-10 EP EP12712669.6A patent/EP2697208A1/en not_active Withdrawn
- 2012-04-10 CN CN201280017754.7A patent/CN103502227A/zh active Pending
- 2012-04-10 MX MX2013010795A patent/MX2013010795A/es not_active Application Discontinuation
- 2012-04-10 WO PCT/EP2012/056408 patent/WO2012139993A1/en active Application Filing
- 2012-04-10 SG SG2013071139A patent/SG193929A1/en unknown
- 2012-04-10 AR ARP120101219A patent/AR085960A1/es unknown
- 2012-04-10 PE PE2013002203A patent/PE20141004A1/es not_active Application Discontinuation
- 2012-04-10 KR KR1020137029827A patent/KR20140002039A/ko active IP Right Grant
- 2012-04-10 EA EA201391468A patent/EA201391468A1/ru unknown
-
2013
- 2013-08-22 IL IL228104A patent/IL228104A0/en unknown
- 2013-08-30 CO CO13206284A patent/CO7071122A2/es not_active Application Discontinuation
- 2013-08-30 CR CR20130432A patent/CR20130432A/es unknown
- 2013-10-07 CL CL2013002871A patent/CL2013002871A1/es unknown
- 2013-10-10 EC ECSP13012967 patent/ECSP13012967A/es unknown
- 2013-11-11 MA MA36414A patent/MA35114B1/fr unknown
-
2014
- 2014-05-02 US US14/268,085 patent/US9115098B2/en not_active Expired - Fee Related
-
2015
- 2015-07-20 US US14/803,746 patent/US20150322054A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CO7071122A2 (es) | 2014-09-30 |
NZ614545A (en) | 2014-10-31 |
CR20130432A (es) | 2013-12-09 |
ECSP13012967A (es) | 2013-11-29 |
US20140243325A1 (en) | 2014-08-28 |
JP2014510769A (ja) | 2014-05-01 |
AR085960A1 (es) | 2013-11-06 |
US20120258962A1 (en) | 2012-10-11 |
EP2697208A1 (en) | 2014-02-19 |
US20150322054A1 (en) | 2015-11-12 |
MA35114B1 (fr) | 2014-05-02 |
CL2013002871A1 (es) | 2014-05-09 |
SG193929A1 (en) | 2013-11-29 |
US9115098B2 (en) | 2015-08-25 |
CN103502227A (zh) | 2014-01-08 |
KR20140002039A (ko) | 2014-01-07 |
US8754075B2 (en) | 2014-06-17 |
AU2012241955A1 (en) | 2013-09-12 |
JP5721157B2 (ja) | 2015-05-20 |
WO2012139993A1 (en) | 2012-10-18 |
MX2013010795A (es) | 2013-12-06 |
EA201391468A1 (ru) | 2014-04-30 |
CA2832467A1 (en) | 2012-10-18 |
IL228104A0 (en) | 2013-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
PE20141005A1 (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
PE20080418A1 (es) | Compuestos y composiciones como moduladores de la via de hedgehog | |
PE20090183A1 (es) | Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5 | |
PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
PE20121480A1 (es) | Aminopirimidinas como inhibidores de syk | |
PE20120081A1 (es) | Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton | |
PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
PE20121440A1 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos | |
PE20141120A1 (es) | Compuestos heterociclicos | |
PE20131153A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
PE20120632A1 (es) | Inhibidores de bace | |
PE20142452A1 (es) | AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2 | |
AR055563A1 (es) | Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente | |
PE20150021A1 (es) | 5-amino[1,4]tiazinas como inhibidores de bace1 | |
PE20130525A1 (es) | Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih | |
PE20120690A1 (es) | Derivados de 5-fluoropirimidinona | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
PE20110875A1 (es) | Derivados de isoindol como inhibidores de bace | |
PE20120937A1 (es) | Compuestos derivados de quinolina y quinoxalina como agentes antivirales | |
PE20081753A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |